Autolus Therapeutics plc American Depositary Share
Last updated September 27, 2026
Organization details
- Legal name
- Autolus Therapeutics plc American Depositary Share
- Former names
- Autolus Therapeutics Ltd
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- United Kingdom
- Headquarters city
- London
- Headquarters country
- United Kingdom
- Fiscal year end
- December
- Ticker symbol
- AUTL
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001730463
Board of directors
-
Christian Itin · Director · Chief Executive OfficerSince 2026
-
Cynthia M. Butitta · DirectorSince 2026
-
Elisabeth Leiderman · DirectorSince 2026
-
John E. Berriman · DirectorSince 2026
-
Linda Bain · DirectorSince 2026
-
Madduri Ravin Rao · DirectorSince 2026
-
Martin Anton Pule · DirectorSince 2026
-
Michael W. Bonney · DirectorSince 2026
-
Robert Azelby · DirectorSince 2026
-
Robert Iannone · DirectorSince 2026
-
Ryan Richardson · DirectorSince 2026
-
William D. Young · DirectorSince 2026
Chief executives
Christian Itin
· Chief Executive Officer
Since March 2026
Board connections
6 of this board's directors also sit on 12 other boards.
- via Robert Azelby
- via Michael W. Bonney
- via Linda Bain
- via Robert Azelby
- via Cynthia M. Butitta
- via Linda Bain
- via Michael W. Bonney
- via Cynthia M. Butitta
- via Robert Iannone
- via William D. Young
- via Robert Azelby
- via Cynthia M. Butitta
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $15,682
- 1 sale by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 2, 2026 | Piccina Cintia Officer (U.S. CCO & Country Gen Manager) | Open-market sale | −6,713 | $2.34 | $15,682 |
| Sep 1, 2026 | Piccina Cintia Officer (U.S. CCO & Country Gen Manager) | Option exercise | +20,000 | $2.35 | $47,000 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.